Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging - An analysis from the EMBRACE study.
Biopsy
Brachytherapy
Cervix Uteri
/ diagnostic imaging
Chemoradiotherapy
/ methods
Cisplatin
/ therapeutic use
Dose Fractionation, Radiation
Female
Humans
Lymph Node Excision
/ statistics & numerical data
Lymph Nodes
/ pathology
Magnetic Resonance Imaging
/ statistics & numerical data
Multicenter Studies as Topic
Neoplasm Staging
/ methods
Observational Studies as Topic
Positron Emission Tomography Computed Tomography
/ statistics & numerical data
Predictive Value of Tests
Prospective Studies
Retrospective Studies
Treatment Outcome
Uterine Cervical Neoplasms
/ diagnosis
Cervical cancer
FIGO
Stage migration
Staging
TNM
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
25
05
2020
accepted:
05
07
2020
pubmed:
17
8
2020
medline:
15
4
2021
entrez:
17
8
2020
Statut:
ppublish
Résumé
To investigate differences in local tumour staging between clinical examination and MRI and differences between FIGO 2009, FIGO 2018 and TNM in patients with primary cervical cancer undergoing definitive radio-chemotherapy. Patients from the prospective observational multi-centre study "EMBRACE" were considered for analysis. All patients had gynaecological examination and pelvic MRI before treatment. Nodal status was assessed by MRI, CT, PET-CT or lymphadenectomy. For this analysis, patients were restaged according to the FIGO 2009, FIGO 2018 and TNM staging system. The local tumour stage was evaluated for MRI and clinical examination separately. Descriptive statistics were used to compare local tumour stages and different staging systems. Data was available from 1338 patients. For local tumour staging, differences between MRI and clinical examination were found in 364 patients (27.2%). Affected lymph nodes were detected in 52%. The two most frequent stages with FIGO 2009 are IIB (54%) and IIIB (16%), with FIGO 2018 IIIC1 (43%) and IIB (27%) and with TNM T2b N0 M0 (27%) and T2b N1 M0 (23%) in this cohort. MRI and clinical examination resulted in a different local tumour staging in approximately one quarter of patients. Comprehensive knowledge of the differential value of clinical examination and MRI is necessary to define one final local stage, especially when a decision about treatment options is to be taken. The use of FIGO 2009, FIGO 2018 and TNM staging system leads to differences in stage distributions complicating comparability of treatment results. TNM provides the most differentiated stage allocation.
Identifiants
pubmed: 32798000
pii: S0090-8258(20)32382-9
doi: 10.1016/j.ygyno.2020.07.007
pii:
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
136-141Subventions
Organisme : Austrian Science Fund FWF
ID : KLI 695
Pays : Austria
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None. The following are the supplementary data related to this article. Supplementary data to this article can be found online at https://doi.org/10.1016/j.ygyno.2020.07.007.